Dirk Witters
Direttore/Membro del Consiglio presso IMMUNOPRECISE ANTIBODIES LTD.
Patrimonio netto: 2 163 $ in data 31/05/2024
Profilo
Dirk Witters has held director positions at ImmunoPrecise Antibodies Ltd.
and BioStrand BV.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 19/01/2024 | 1 950 ( 0.01% ) | 2 163 $ | 31/05/2024 |
Posizioni attive di Dirk Witters
| Società | Posizione | Inizio |
|---|---|---|
| IMMUNOPRECISE ANTIBODIES LTD. | Direttore/Membro del Consiglio | 05/09/2023 |
BioStrand BV
 BioStrand BV Miscellaneous Commercial ServicesCommercial Services Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| IMMUNOPRECISE ANTIBODIES LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
BioStrand BV
BioStrand BV Miscellaneous Commercial ServicesCommercial Services Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million. | Commercial Services |
- Borsa valori
- Insiders
- Dirk Witters
